SCHEMBL1485944

SCHEMBL1485944

C=CNc1ccccc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
HTT P42858 1/20 0.48
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
GAA P10253 4/20 0.43
DHODH Q02127 1/20 0.43
KDM4E B2RXH2 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
RECQL P46063 1/20 0.41
TSHR P16473 1/20 0.41
ACHE P22303 1/20 0.41
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
EGFR P00533 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10394835 0.82 KEAP1 (0.47) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL27004797 0.82 ALDH1A1 (0.36) ALDH1A1TSHR
Benzene SCHEMBL28341119 0.80 KEAP1 (0.46) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL13257963 0.80 NPC1 (0.54) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL22917221 0.80 RAB9A (0.42) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL22646247 0.79 RECQL (0.44) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL3127028 0.78 MAPT (0.50) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL10893987 0.76 MAPT (0.48) MAPTHTTNPC1RAB9AALDH1A1
SCHEMBL22174381 0.76 POLB (0.43) MAPTNPC1RAB9AALDH1A1HPGD
SCHEMBL11289154 0.76 MAPT (0.48) MAPTHTTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2166060-B1 Stabilized aqueous polymer compositions TOUGAS OILFIELD SOLUTIONS GMBH (DE) 2016-08-10 EP claimed
US-20240218244-A1 CURED FILM AND DISPLAY DEVICE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-07-04 US disclosed
WO-2023212244-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed
US-20230277547-A1 SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-07 US disclosed
US-20230257571-A1 RESIN COMPOSITION, RESIN FILM, AND DISPLAY DEVICE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-08-17 US disclosed
US-20230242548-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
US-20230140430-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2023-05-04 US disclosed
US-20230130516-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2023-04-27 US disclosed
US-20230127326-A1 C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2023-04-27 US disclosed
WO-2004043367-A2 FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-27 WO disclosed
WO-2004000788-A1 UREIDO-SUBSTITUTED ANILINE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-31 WO disclosed
WO-1997043126-A1 IMPROVED PROCESS FOR THE PRODUCTION OF SCRATCH-OFF CARDS THE BRITISH PRINTING COMPANY LTD. (GB) 1997-11-20 WO disclosed
US-4978789-A CATALYTIC DEHYDROGENATION USING A MIXED OXIDE CONTAINING IRON AND SILICON; DEALKENYLATION OF ALKYL PHENOLS AND ANILINES MITSUI CHEMICALS, INC. (JP) 1990-12-18 US disclosed
US-4898915-A ACRYLIC ESTERS, NITRILES OR ACIDS COMONOMERS WITH VINYL IMIDES; DEPROTECTING WITH HYDRAZINE ANTISTATIC, THICKENERS UNIVERSITY OF AKRON (US) 1990-02-06 US disclosed
EP-0206621-B1 PROCESS FOR DISPROPORTIONATING SILANES MITSUI TOATSU CHEMICALS, Inc. (JP) 1989-11-15 EP disclosed
EP-0205317-B1 PROCESS FOR PRODUCTION OF ALKENYL SUBSTITUTED AROMATIC COMPOUND MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-12-14 EP disclosed
EP-0206621-A1 Process for disproportionating silanes MITSUI TOATSU CHEMICALS, Inc. (JP) 1986-12-30 EP disclosed
EP-0205317-A1 Process for production of alkenyl substituted aromatic compound MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1986-12-17 EP disclosed
US-4323662-A Thermosetting resin compositions comprising bismaleimides and alkenylaniline derivatives MITSUI TOATSU CHEMICALS, INC. (JP) 1982-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127326-A1 C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS TLR7, TLR3, TLR9 MAPT 4253/4885HTT 4838/4885NPC1 2053/4885
US-20230277547-A1 SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS DTYMK, POLK, TOP1 MAPT 2480/4885HTT 742/4885NPC1 1174/4885
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML MAPT 2170/4885HTT 3116/4885NPC1 1422/4885
US-20230130516-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS TLR7, TLR1, TLR9 MAPT 3546/4885HTT 4750/4885NPC1 2220/4885
US-20230140430-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS TLR7, TLR1, TLR9 MAPT 3546/4885HTT 4750/4885NPC1 2220/4885
US-20230242548-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER KRAS, HRAS, NRAS MAPT 3731/4885HTT 2363/4885NPC1 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.